# Efficacy and Safety Trial of Subcutaneous Immunotherapy in Mite Induced Asthma

> **NCT00492076** · PHASE4 · COMPLETED · sponsor: **ALK-Abelló A/S** · enrollment: 45 (actual)

## Conditions studied

- Allergic Asthma

## Interventions

- **BIOLOGICAL:** Pangramin Plus D. pteronyssinus 100%

## Key facts

- **NCT ID:** NCT00492076
- **Lead sponsor:** ALK-Abelló A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-10
- **Primary completion:** 2008-05
- **Final completion:** 2008-05
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2008-10-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00492076

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00492076, "Efficacy and Safety Trial of Subcutaneous Immunotherapy in Mite Induced Asthma". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00492076. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*